What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Gaia Giannone, Andrea Milani, Elena Geuna, Danilo Galizia, Federica Biello, Filippo Montemurro

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish
Pages (from-to)5-9
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Issue number1
Publication statusPublished - Jan 2 2019


  • adjuvant
  • breast cancer
  • chemotherapy
  • HER2
  • lapatinib
  • metastatic
  • neratinib
  • pertuzumab
  • T-DM1
  • trastuzumab

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this